In summary, recent data point to a regulatory window for the expression level of SHIP1, which must neither be undercut (e.g., in T-ALL and CML) nor exceeded (e.g., in Ph-positive B-ALL and ETV6-RUNX1-positive B-ALL). Here, INPP5D is linked to acute lymphoblastic leukemia.